Non-steroidal anti-inflammatory drugs
(NSAIDs) is a class of powerful analgesics, distinguished by their
non-steroidal chemical structure. These drugs are frequently prescribed
to reduce pain caused due to inflammation. These are considered the
first line of treatment in pain management due to three basic
properties: analgesic, antipyretic, and anti-inflammatory. Usage of
non-steroidal anti-inflammatory drugs in pain management dates back to
the 1960s and 1970s when the first few key molecules such as diclofenac
and ibuprofen were approved by the U.S. FDA. The patents for all (except
one) the key branded formulations in this market have expired,
rendering the market completely generic and even over-the-counter (OTC)
for some drugs. The most common OTC drugs in this class include aspirin
and ibuprofen used in the treatment of headache, body ache, sports
injuries, and menstrual cramps. Non-steroidal anti-inflammatory drugs
are categorized into various groups: salicylates (diflunisal, salsalate,
and acetylsalicylic acid), acetic acid derivatives (diclofenac,
ketorolac, indomethacin, and etodolac), selective COX-2 inhibitors
(celecoxib), proprionic acid derivatives (ibuprofen, naproxen,
ketoprofen, and fenoprofen), fenamic acid derivatives (meclofenamic
acid, tolfenamic acid, and mefenamic acid), and enolic acid derivatives
(oxicam, piroxicam, tenoxicam and lornoxicam).
Report Overview @ https://www.transparencymarketresearch.com/non-steroidal-anti-inflammatory-drugs-market.html
Based on dosage form, the non-steroidal
anti-inflammatory drugs market has been segmented into oral, topical,
and injectable. The injectable segment is expected to witness rapid
growth owing to higher efficacy. Non-steroidal anti-inflammatory drugs
are indicated for postoperative pain, bone and joint pain (rheumatoid
arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis),
menstrual pain, tooth ache, and others. The bone and joint pain segment
is expected to be driven by rising prevalence of bone and joint
disorders such as rheumatoid arthritis and osteoarthritis, and increase
in number of hospital surgeries. Rising incidence of pain disorders,
increase in geriatric population with high risk of various diseases,
growing adoption of pain management therapeutics among end-users, and
favorable regulatory scenario and health care reforms boost the growth
of the non-steroidal anti-inflammatory drugs market. However, entry of
new innovative therapeutic analgesics, stringent government regulations,
and side effect associated with non-steroidal anti-inflammatory drugs
restrain the non-steroidal anti-inflammatory drugs market.
In terms of region, the non-steroidal
anti-inflammatory drugs market has been classified into North America,
Latin America, Europe, Asia Pacific, and Middle East & Africa. North
America dominates the non-steroidal anti-inflammatory drugs market,
followed by Europe, due to increase in geriatric population suffering
from bone and joint disorders, rising junk food habits & sedentary
lifestyle, and increase in incidence and prevalence of bone and joint
disorders. Asia Pacific is an emerging market for non-steroidal
anti-inflammatory drugs owing to rising health care infrastructure,
gradual development of medical infrastructure, growing awareness, and
large patient pool. However, lack of proper treatment and low patient
awareness are factors restraining the non-steroidal anti-inflammatory
drugs market in regions such as Middle East & Africa and Latin
America.
Major players operating in the
non-steroidal anti-inflammatory drugs market include Bayer HealthCare
Pharmaceuticals LLC, Pfizer, Inc., Reckitt Benckiser Group plc, Novartis
International AG, and Daiichi Sankyo Company, Limited.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment